Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage immuno-oncology company developing Temferon™, a hematopoietic stem cell therapy platform aimed at solid tumor cancers. The GNTA news feed on Stock Titan aggregates company-issued updates, regulatory disclosures, and other coverage that shed light on how this platform is progressing through clinical development and corporate milestones.
News about Genenta frequently centers on its Temferon clinical programs, including the TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter and Phase 1/2a work in metastatic renal cell carcinoma and other genitourinary tumors. Company releases discuss survival trends, long-term follow-up observations, and exploratory immune findings related to tumor microenvironment reprogramming and T cell responses.
Investors following GNTA can also expect coverage of financing transactions such as registered direct offerings of American Depositary Shares, mandatory convertible bond financings with institutional partners, and the use of at-the-market facilities, as well as updates on cash and short-term investments in the context of funding clinical trials. Additional news items highlight strategic collaborations with organizations like Anemocyte and AGC Biologics for plasmid DNA and cell therapy manufacturing, along with participation in biotech conferences and sector events.
Corporate governance and leadership developments, including board appointments, changes in executive roles, amendments to by-laws, and disclosures about insider share ownership, are also reported through Genenta’s press releases and Form 6-K filings. For readers tracking GNTA stock, this news page provides a centralized view of the company’s clinical, financial, and strategic updates. Bookmark the GNTA news section to review new releases and historical announcements as Genenta advances its immuno-oncology platform.
Summary not available.
Summary not available.
Summary not available.
Genenta Science (NASDAQ: GNTA) announced its fiscal year 2022 financial results, revealing a net loss of €8.5 million, an increase from €5.5 million in 2021. The loss includes a net exchange rate gain of €2.3 million from USD to EUR conversion. The company reported no revenues for 2022, with R&D expenses rising to €5.3 million and G&A expenses at €5.7 million. Genenta holds a €6.4 million tax credit and €29.8 million in cash, estimated to sustain operations into Q1 2025. CEO Pierluigi Paracchi emphasized progress on their lead technology, Temferon, aimed at treating glioblastoma. The annual report is available on the company's investor relations site.
Genenta Science (NASDAQ: GNTA) has announced an amendment to its license agreement with Ospedale San Raffaele (OSR), now allowing access to all solid tumor indications, pending governmental consent. This expansion is expected to enhance Genenta's intellectual property position and treatment options for various cancers. CEO Pierluigi Paracchi highlighted promising preliminary data from the ongoing glioblastoma study, bolstering the decision for broader access. The amended agreement requires approval from the Italian government, which must respond within 90 days for the changes to take effect.
Genenta Science (NASDAQ: GNTA) announced that the FDA has granted Orphan Drug Designation to Temferon™ for glioblastoma multiforme (GBM) treatment. The designation aims to promote the development of Temferon™, a cell therapy targeting tumor microenvironments with immunomodulatory molecules. This decision is expected to enhance Genenta's clinical program addressing the significant unmet medical need in GBM, where about 60% have unmethylated MGMT promoter status. The ODD provides benefits such as federal grants, tax credits for trials, and a seven-year marketing exclusivity post-approval.
Genenta Science (NASDAQ: GNTA) has announced a development and manufacturing service agreement with AGC Biologics S.p.A. to produce cell therapy lentivirus-based products for its clinical programs. This partnership aims to enhance Genenta's ongoing Phase 1/2 clinical trial, particularly for its treatment targeting glioblastoma multiforme. Following the acquisition of Molecular Medicine's facility by AGC Biologics, the collaboration indicates a strategic expansion, emphasizing the importance of the manufacturing process in clinical progression. CEO Pierluigi Paracchi highlighted expectations for their treatment to significantly impact solid tumors.
Genenta Science (Nasdaq: GNTA) will present data at the Society for Immunotherapy of Cancer's annual meeting, indicating that its product candidate, Temferon, has induced a pro-inflammatory state in glioblastoma patients, potentially inhibiting tumor growth. Preclinical studies suggest that Temferon activates immune responses linked to tumor responses and eradication in certain cases. The CEO highlighted the unmet need in glioblastoma treatment, suggesting Temferon's potential as a disease-modifying intervention. The findings will be presented in Boston from November 8-12, 2022.
Genenta Science (Nasdaq: GNTA) released its financial results for the six months ended June 30, 2022, reporting a net loss of €2.1 million, a reduction from a €4.0 million loss in the same period last year. The company has no revenues but holds €34.7 million in cash, sufficient to fund operations through 2024. Significant progress was made in the Phase 1/2a trial of Temferon for glioblastoma, with a median overall survival of 17 months reported. The trial has escalated to a higher dosing cohort and aims to assess new conditioning regimens for enhanced efficacy.
Genenta Science (NASDAQ: GNTA), a clinical-stage immune-oncology company, is set to showcase its innovative therapies at upcoming scientific and investor conferences. Key events include the Roth Inaugural Healthcare Opportunities on October 6 in New York and the European Society of Gene & Cell Therapy Congress from October 11-14 in Edinburgh, UK. The Society for Immunotherapy of Cancer’s Annual Meeting will follow from November 8-12 in Boston, MA. These presentations will feature groundbreaking research on genetically-modified hematopoietic stem cells and autologous macrophage-based immunotherapy targeting solid tumors.